CA
TBPH icon

Clearstead Advisors’s Theravance Biopharma TBPH Stock Holding History

Clearstead Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$136 Buy
+8
New +$132 ﹤0.01% 3291
2025
Q4 		– Sell
-20
Closed -$292 – 3225
2025
Q3 		$292 Buy
+20
New +$253 ﹤0.01% 2808

Other funds holding TBPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SSA
Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
MCC
Money Concepts Capital Palm Beach Gardens, Florida $2.16B AUM 28.67% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Clearstead Advisors's TBPH Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Theravance Biopharma (TBPH) in Q2 2026: 8 shares worth $136. The stake represents ﹤0.01% of the portfolio and ranks #3291 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in TBPH as recently as Q3 2025.

Clearstead Advisors first reported a position in TBPH in Q3 2025 and has held it in 2 quarters since. The position peaked at $292 in Q3 2025. 56 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Clearstead Advisors held 8 shares of Theravance Biopharma worth $136 as of Q2 2026.
  • Theravance Biopharma was a new Clearstead Advisors position in Q2 2026.
  • Theravance Biopharma made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3291 holding.
  • Clearstead Advisors first reported a position in Theravance Biopharma in Q3 2025 and has held it in 2 quarters since.
  • Clearstead Advisors's Theravance Biopharma position peaked at $292 in Q3 2025.
  • 56 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.